ABCL
Price
$3.53
Change
+$0.47 (+15.36%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
1.04B
34 days until earnings call
AKBA
Price
$2.38
Change
+$0.01 (+0.42%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
521.45M
49 days until earnings call
Ad is loading...

ABCL vs AKBA

Header iconABCL vs AKBA Comparison
Open Charts ABCL vs AKBABanner chart's image
AbCellera Biologics
Price$3.53
Change+$0.47 (+15.36%)
Volume$80.17K
Capitalization1.04B
Akebia Therapeutics
Price$2.38
Change+$0.01 (+0.42%)
Volume$21.51K
Capitalization521.45M
ABCL vs AKBA Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. AKBA commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and AKBA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (ABCL: $3.06 vs. AKBA: $2.37)
Brand notoriety: ABCL and AKBA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 131% vs. AKBA: 249%
Market capitalization -- ABCL: $903.82M vs. AKBA: $517.09M
ABCL [@Biotechnology] is valued at $903.82M. AKBA’s [@Biotechnology] market capitalization is $517.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $341.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileAKBA’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • AKBA’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 4 TA indicator(s) are bullish while AKBA’s TA Score has 2 bullish TA indicator(s).

  • ABCL’s TA Score: 4 bullish, 3 bearish.
  • AKBA’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than AKBA.

Price Growth

ABCL (@Biotechnology) experienced а +10.47% price change this week, while AKBA (@Biotechnology) price change was +25.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.78%. For the same industry, the average monthly price growth was +2.45%, and the average quarterly price growth was -2.46%.

Reported Earning Dates

ABCL is expected to report earnings on May 13, 2025.

AKBA is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+1.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.04B) has a higher market cap than AKBA($521M). AKBA YTD gains are higher at: 24.737 vs. ABCL (4.437). AKBA has higher annual earnings (EBITDA): 4.3M vs. ABCL (-202.4M). ABCL has more cash in the bank: 643M vs. AKBA (34M). AKBA has less debt than ABCL: AKBA (48.6M) vs ABCL (71.4M). AKBA has higher revenues than ABCL: AKBA (170M) vs ABCL (33M).
ABCLAKBAABCL / AKBA
Capitalization1.04B521M200%
EBITDA-202.4M4.3M-4,710%
Gain YTD4.43724.73718%
P/E RatioN/AN/A-
Revenue33M170M19%
Total Cash643M34M1,891%
Total Debt71.4M48.6M147%
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
83
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLAKBA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 15 days ago
90%
Bullish Trend 15 days ago
90%
Momentum
ODDS (%)
Bullish Trend 15 days ago
85%
Bearish Trend 15 days ago
80%
MACD
ODDS (%)
Bullish Trend 15 days ago
80%
N/A
TrendWeek
ODDS (%)
Bullish Trend 15 days ago
78%
Bearish Trend 15 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 15 days ago
73%
Bearish Trend 15 days ago
85%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend 27 days ago
86%
Declines
ODDS (%)
Bearish Trend 15 days ago
86%
Bearish Trend 15 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 15 days ago
90%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIREX12.410.22
+1.80%
JHancock Real Estate Securities 1
TINFX24.340.41
+1.71%
Thornburg International Growth R5
PBCJX46.870.61
+1.32%
Principal Blue Chip J
BFGUX50.570.39
+0.78%
Baron Focused Growth R6
AAIIX7.310.05
+0.69%
Ancora Income I

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with VCYT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+3.03%
VCYT - ABCL
56%
Loosely correlated
+7.44%
BEAM - ABCL
53%
Loosely correlated
+4.65%
PRME - ABCL
53%
Loosely correlated
+0.69%
AURA - ABCL
53%
Loosely correlated
+2.06%
DNA - ABCL
52%
Loosely correlated
+6.93%
More

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+14.49%
ABOS - AKBA
43%
Loosely correlated
-1.21%
FBIO - AKBA
40%
Loosely correlated
-0.53%
BEAM - AKBA
40%
Loosely correlated
+4.65%
ABCL - AKBA
40%
Loosely correlated
+3.03%
KOD - AKBA
39%
Loosely correlated
+4.60%
More